PTGS2 and colorectal cancer: Studies have shown that erythromycin suppresses pro-inflammatory signaling by inhibiting NF-κB activation, which in turn reduces the expression of downstream targets such as interleukin-6 and COX2 in colorectal cancer cell lines [160].